Most cited article(s)

You have access
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes.
M Alkondon and E X Albuquerque

Journal of Pharmacology and Experimental Therapeutics June 1993, 265 (3) 1455-1473;
You have access
Post-Translational Control of Endothelial Nitric Oxide Synthase: Why Isn't Calcium/Calmodulin Enough?
David Fulton, Jean-Philippe Gratton and William C. Sessa

Journal of Pharmacology and Experimental Therapeutics December 2001, 299 (3) 818-824;
You have access
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
R. Scott Obach, Robert L. Walsky, Karthik Venkatakrishnan, Emily A. Gaman, J. Brian Houston and Larry M. Tremaine

Journal of Pharmacology and Experimental Therapeutics January 2006, 316 (1) 336-348; DOI: https://doi.org/10.1124/jpet.105.093229
You have access
A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS
J. T. LITCHFIELD and F. WILCOXON

Journal of Pharmacology and Experimental Therapeutics June 1949, 96 (2) 99-113;
You have access
Ro 25–6981, a Highly Potent and Selective Blocker of N-Methyl-d-aspartate Receptors Containing the NR2B Subunit. Characterization in Vitro
G. Fischer, V. Mutel, G. Trube, P. Malherbe, J. N. C. Kew, E. Mohacsi, M. P. Heitz and J. A. Kemp

Journal of Pharmacology and Experimental Therapeutics December 1997, 283 (3) 1285-1292;
You have access
Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
M Bourrié, V Meunier, Y Berger and G Fabre

Journal of Pharmacology and Experimental Therapeutics April 1996, 277 (1) 321-332;
You have access
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
A M Badger, J N Bradbeer, B Votta, J C Lee, J L Adams and D E Griswold

Journal of Pharmacology and Experimental Therapeutics December 1996, 279 (3) 1453-1461;
You have access
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
M Clozel, V Breu, G A Gray, B Kalina, B M Löffler, K Burri, J M Cassal, G Hirth, M Müller and W Neidhart

Journal of Pharmacology and Experimental Therapeutics July 1994, 270 (1) 228-235;
You have access
A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine
Scott M. DeWire, Dennis S. Yamashita, David H. Rominger, Guodong Liu, Conrad L. Cowan, Thomas M. Graczyk, Xiao-Tao Chen, Philip M. Pitis, Dimitar Gotchev, Catherine Yuan, Michael Koblish, Michael W. Lark and Jonathan D. Violin

Journal of Pharmacology and Experimental Therapeutics March 2013, 344 (3) 708-717; DOI: https://doi.org/10.1124/jpet.112.201616
You have access
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
Bryan A. Ward, J. Christopher Gorski, David R. Jones, Stephen D. Hall, David A. Flockhart and Zeruesenay Desta

Journal of Pharmacology and Experimental Therapeutics July 2003, 306 (1) 287-300; DOI: https://doi.org/10.1124/jpet.103.049601

Main menu

User menu

Search

Most cited article(s)

Pages

Navigate

More Information

ASPET's Other Journals